Elena Pegolo

Mrs. Elena Pegolo

Department of Information Engineering, University of Padova, Italy
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
Edoardo BianchiniEdoardo Bianchini
Edoardo Bianchini
DRDomiziana Rinaldi
Domiziana Rinaldi
MAMarika Alborghetti
Marika Alborghetti
MSMarta Simonelli
Marta Simonelli
FDFlavia D’audino
Flavia D’audino
Francesco Ernesto PontieriFrancesco Ernesto Pontieri
Francesco Ernesto Pontieri
Facial movements are crucial for social and emotional interaction and well-being. Reduced facial expressions (i.e., hypomimia) is a common feature in patients with Parkinson’s disease (PD) and previous studies linked this manifestation to both motor symptoms of the disease and altered emotion recognition and processing. Nevertheless, research on facial motor impairment in PD has been rather scarce and only a limited number of clinical evaluation tools are available, often suffering from poor validation processes and high inter- and intra-rater variability. In recent years, the availability of technology-enhanced quantification methods of facial movements, such as automated video analysis and machine learning application, led to increasing interest in studying hypomimia in PD. In this narrative review, we summarize the current knowledge on pathophysiological hypotheses at the basis of hypomimia in PD, with particular focus on the association between reduced facial expressions and emotional processing and analyze the current evaluation tools and management strategies for this symptom, as well as future research perspectives.

10 February 2022 in Sensors
Verified
Journal Article
Open access
PDF file
Elena PegoloElena Pegolo
Elena Pegolo
DVDaniele Volpe
Daniele Volpe
ACAlberto Cucca
Alberto Cucca
LRLucia Ricciardi
Lucia Ricciardi
ZIMI SAWACHAZIMI SAWACHA
ZIMI SAWACHA
Parkinson’s disease (PD) is a neurological disorder that mainly affects the motor system. Among other symptoms, hypomimia is considered one of the clinical hallmarks of the disease. Despite its great impact on patients’ quality of life, it remains still under-investigated. The aim of this work is to provide a quantitative index for hypomimia that can distinguish pathological and healthy subjects and that can be used in the classification of emotions. A face tracking algorithm was implemented based on the Facial Action Coding System. A new easy-to-interpret metric (face mobility index, FMI) was defined considering distances between pairs of geometric features and a classification based on this metric was proposed. Comparison was also provided between healthy controls and PD patients. Results of the study suggest that this index can quantify the degree of impairment in PD and can be used in the classification of emotions. Statistically significant differences were observed for all emotions when distances were taken into account, and for happiness and anger when FMI was considered. The best classification results were obtained with Random Forest and kNN according to the AUC metric.

21 October 2024 in Brain
Verified
Journal Article
Open access
PDF file
BSBart Swinnen
Bart Swinnen
CHColin W Hoy
Colin W Hoy
Elena PegoloElena Pegolo
Elena Pegolo
BIBryony Ishihara
Bryony Ishihara
EMElena Ubeda Matzilevich
Elena Ubeda Matzilevich
LRLucia Ricciardi
Lucia Ricciardi
Neuropsychiatric symptoms are common and disabling in Parkinson’s disease (PD), with troublesome anxiety occurring in one-third of patients. Management of anxiety in PD is challenging, hampered by insufficient insight into underlying mechanisms, lack of objective anxiety measurements, and largely ineffective treatments. In this study, we assessed the intracranial neurophysiological correlates of anxiety in PD patients treated with deep brain stimulation (DBS) in the laboratory and at home. We hypothesized that low-frequency (theta-alpha) activity would be associated with anxiety. We recorded local field potentials (LFP) from the subthalamic nucleus (STN) or the globus pallidus pars interna (GPi) DBS implants in three PD cohorts: 1) patients with recordings (STN) performed in hospital at rest via perioperatively externalized leads, without active stimulation, both ON or OFF dopaminergic medication; 2) patients with recordings (STN or GPi) performed at home while resting, via a chronically implanted commercially available sensing-enabled neurostimulator (Medtronic PerceptTM device), ON dopaminergic medication, with stimulation both on or off; 3) patients with recordings performed at home while engaging in a behavioral task via STN and GPi leads and electrocorticography paddles over premotor cortex connected to an investigational sensing-enabled neurostimulator, ON dopaminergic medication, with stimulation both on or off. Trait anxiety was measured with validated clinical scales in all participants, and state anxiety was measured with momentary assessment scales at multiple time points in the two at-home cohorts. Power in theta (4-8 Hz) and alpha (8-12 Hz) ranges were extracted from the LFP recordings, and their relation with anxiety ratings was assessed using linear mixed-effects models. In total, 33 PD patients (59 hemispheres) were included. Across three independent cohorts, with stimulation off, basal ganglia theta power was positively related to trait anxiety (all p<0.05). Also in a naturalistic setting, with individuals at home at rest with stimulation and medication ON, basal ganglia theta power was positively related to trait anxiety (p<0.05). This relationship held regardless of the hemisphere and DBS target. There was no correlation between trait anxiety and premotor cortical theta-alpha power. There was no within-patient association between basal ganglia theta-alpha power and state anxiety. We showed that basal ganglia theta activity indexes trait anxiety in PD. Our data suggest that theta could be a possible physiomarker of neuropsychiatric symptoms and specifically of anxiety in PD, potentially suitable for guiding advanced DBS treatment tailored to the individual patient’s needs, including non-motor symptoms.

11 June 2025 in Movement Disorders
Verified
Journal Article
Open access
LRLucia Ricciardi
Lucia Ricciardi
FCFrancescopaolo Cucinotta
Francescopaolo Cucinotta
Elena PegoloElena Pegolo
Elena Pegolo
AAArturo Abundes‐Corona
Arturo Abundes‐Corona
BIBryony Ishihara
Bryony Ishihara
Alfonso FasanoAlfonso Fasano
Alfonso Fasano
Background: High frequency deep brain stimulation of the subthalamic nucleus (STN‐DBS) is a well‐established therapy for Parkinson's disease (PD) motor symptoms, however, its effect on non‐motor symptoms is controversial. Low frequency DBS can improve cognition, but its effects on motor functions are detrimental.Objective: Our goal was to evaluate the effect on verbal fluency (VF) of dual frequency STN‐DBS combining high and low frequency (130 + 10 Hz) as compared to 130 Hz or 10 Hz alone and to OFF stimulation. The effect on motor symptoms, working memory, and subjective feelings was also assessed.Methods: We used a randomized order of experimental conditions with a double‐blind design to assess the effects of 130 Hz, 10 Hz, and 130 + 10 Hz stimulation as compared to OFF stimulation in 18 PD patients with STN‐DBS. In each condition, participants completed: phonemic and action VF, N‐back task, and visual analogue scales for fatigue and stress level. Motor functions and gait velocity were also assessed.Friedman analysis of variance were conducted to determine whether change scores from baseline OFF stimulation, in our primary (VF) and secondary outcomes measures (motor functions, N‐back task, subjective feelings) were different in the three stimulation conditions.Results: VF improved more in the 130 + 10 Hz condition than 130 Hz condition (P = 0.006); there was no difference between 130 + 10 Hz and 10 Hz (P = 0.2) and between 130HZ and 10 Hz (P = 0.6). There was a significant difference among the stimulation conditions for the motor score (χ2(2) = 11.1, P = 0.004), it being worse at 10 Hz than 130 Hz (P = 0.002) and 130 + 10 Hz (P = 0.01).Conclusions: Dual frequency STN‐DBS improves phonemic VF while maintaining a beneficial effect on motor signs of PD. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

27 March 2023 in IEEE Transactions on Biomedical Engineering
Verified
Journal Article
Open access
EFEdoardo Faggionato
Edoardo Faggionato
AGAlessandro Guazzo
Alessandro Guazzo
Elena PegoloElena Pegolo
Elena Pegolo
RCRuggero Carli
Ruggero Carli
BMBruschetta Mattia
Bruschetta Mattia
SFSimone Del Favero
Simone Del Favero
Objective: Effective dosing of anticoagulants aims to prevent blood clot formation while avoiding hemorrhages. This complex task is challenged by several disturbing factors and drug-effect uncertainties, requesting frequent monitoring and adjustment. Biovariability in drug absorption and action further complicates titration and calls for individualized strategies. In this paper, we propose an adaptive closed-loop control algorithm to assist in warfarin therapy management. Methods: The controller was designed and tested in silico using an established pharmacometrics model of warfarin, which accounts for inter-subject variability. The control algorithm is an adaptive Model Predictive Control (a-MPC) that leverages a simplified patient model, whose parameters are updated with a Bayesian strategy. Performance was quantitatively evaluated in simulations performed on a population of virtual subjects against an algorithm reproducing medical guidelines (MG) and an MPC controller available in the literature (l-MPC). Results: The proposed a-MPC significantly (p $< $ 0.05) lowers rising time (2.8 vs. 4.4 and 11.2 days) and time out of range (3.3 vs. 7.2 and 12.9 days) with respect to both MG and l-MPC, respectively. Adaptivity grants a significantly (p $< $ 0.05) lower number of subjects reaching unsafe INR values compared to when this feature is not present (8.9% vs.15% of subjects presenting an overshoot outside the target range and 0.08% vs. 0.28% of subjects reaching dangerous INR values). Conclusion: The a-MPC algorithm improve warfarin therapy compared to the benchmark therapies. Significance: This in-silico validation proves effectiveness of the a-MPC algorithm for anticoagulant administration, paving the way for clinical testing.